Combined endothelin receptor antagonist and transcatheter interventional therapy of patent ductus arteriosus with severe pulmonary artery hypertension

International Journal of Cardiology

Volumn 116, Issue 3, 2007, Pages 427-429

  Ussia, Gian Paolo ^a   Mulè, Massimiliano ^a   Caruso, Elio ^a   Aiello, Rosa ^a   Tamburino, Corrado ^a  

^a Ferrarotto Hospital   (Italy)

Author keywords

Amplatzer occluder; Bosentan; Patent ductus arteriosus; Pulmonary artery hypertension

Indexed keywords

BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST;

ADULT; ARTICLE; CASE REPORT; CONGENITAL HEART DISEASE; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HEART CATHETERIZATION; HEART SURGERY; HUMAN; LUNG BLOOD FLOW; LUNG CAPACITY; LUNG HEMODYNAMICS; MALE; PATENT DUCTUS ARTERIOSUS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; DUCTUS ARTERIOSUS, PATENT; HEART CATHETERIZATION; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 33847163650     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.03.080     Document Type: Article

References (10)

1. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt (the Croonian lectures). Br Med J 1958;ii:701-9, 755-62.
2. Vogel M., Berger F., Kramer A., Alexi-Meshkishvili V., and Lange P.E. Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects. Heart 82 1 (Jul 1999) 30-33
3. Pass R.H., Hijazi Z., Hsu D.T., Lewis V., and Hellenbrand W.E. Multicenter USA Amplatzer patent ductus arteriosus occlusion device trial: initial and one-year results. J Am Coll Cardiol 44 3 (Aug 4 2004) 513-519
4. Abraham R.M. Congenital diseases of the heart: clinical-physiological considerations (2001), Futura Publishing, Armonk, NY
5. Humbert M., Morrell N.W., Archer S.L., et al. Cellular and molecular pathobiology of pulmonary arterial hypertens. J Am Coll Cardiol 43 suppl 12S (2004) 13S-24S
6. Pietra G.G., Capron F., Stewart S., et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43 suppl 12S (Jun 16 2004) 25S-32S
7. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 12 (2002) 896-903
8. Schulze-Neick I., Gilbert N., Ewert R., et al. Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of Bosentan therapy. Am Heart J 150 4 (2005) 716.e7-716.e12
9. de Lezo J.S., Medina A., Romero M., et al. Effectiveness of percutaneous device occlusion for atrial septal defect in adult patients with pulmonary hypertension. Am Heart J 144 5 (2002) 877-880
10. Schwerzmann M., Zafar M., McLaughlin P.R., Chamberlain D.W., Webb G., and Granton J. Atrial septal defect closure in a patient with "irreversible" pulmonary hypertensive arteriopathy. Int J Cardiol 29 (2005)